- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Santa Monica, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 599
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Not listed
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 264
- States / cities
- Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more
- Conditions
- Colorectal Neoplasms
- Interventions
- CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Ceralasertib, Olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer Of, Non-Resectable
- Interventions
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two, Checkpoint Inhibitor, Immune
- Drug
- Lead sponsor
- Omega Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Tumours, Gynecological
- Interventions
- Mo-Rez, Dostarlimab, Bevacizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- La Jolla, California • Aurora, Colorado • Rochester, New York + 2 more
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
- Interventions
- AZD6750, rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Breast Cancer, Solid Tumor, Adult
- Interventions
- APG-2575, Palbociclib
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Austin, Texas • Houston, Texas + 1 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
- Biological · Drug
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Anaheim, California • Orange, California • Denver, Colorado + 4 more
- Conditions
- Bladder Cancer
- Interventions
- Abraxane
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- BG-C477, Tislelizumab, Chemotherapy
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Goodyear, Arizona • Duarte, California • Aurora, Colorado + 7 more
- Conditions
- NSCLC
- Interventions
- Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection
- Device · Drug · Other
- Lead sponsor
- Galvanize Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Interventions
- Azacitidine, Lenalidomide
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Solid Tumor
- Interventions
- Topotecan, Sorafenib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Hartford, Connecticut • Wilmington, Delaware + 6 more
- Conditions
- Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
- Interventions
- Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
- Drug · Radiation · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2037
- U.S. locations
- 679
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 65 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 857
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more
- Conditions
- Neoplasms
- Interventions
- GSK3174998, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Interventions
- contrast-enhanced magnetic resonance imaging
- Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Advanced Solid Tumor
- Interventions
- BGB-58067, BG-89894, Standard of Care Therapy
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Los Alamitos, California • Los Angeles, California • Celebration, Florida + 8 more
- Conditions
- B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
- Interventions
- IKS03
- Drug
- Lead sponsor
- Iksuda Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cancer
- Interventions
- TTX-080, pembrolizumab, cetuximab, FOLFIRI
- Drug
- Lead sponsor
- Tizona Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
- Conditions
- Richter Syndrome
- Interventions
- Venetoclax, DA-EPOCH-R, R-CHOP
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Columbus, Ohio • Houston, Texas